Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ampligen Will Be Early Test Of FDA Consolidation Of Chronic Fatigue Drug Reviews

Executive Summary

FDA’s decision to consolidate oversight for chronic fatigue syndrome treatments in the Division of Pulmonary, Allergy and Rheumatology Products will face an early test with Hemispherx Biopharma Inc.’s expected submission of an amended NDA for its investigational agent Ampligen in the third quarter.

You may also be interested in...



FDA Uses AdComm Process To Shine Light On Ampligen’s Troubled Development

December’s Arthritis Advisory Committee review of Hemispherx’s drug provided FDA with the first public opportunity to explain in detail why the chronic fatigue syndrome drug, in development for almost 25 years, has not passed regulatory muster to date.

FDA Takes Dim View Of Ampligen For Chronic Fatigue Syndrome

In review documents released ahead of a Dec. 20 advisory committee meeting, agency questions the validity of Hemispherx’s post-hoc efficacy analyses and raises concerns about adverse events and the reliability of the safety data.

Hemispherx Ampligen Advisory Cmte. Will Be Early Test Of FDA Focus On Chronic Fatigue Syndrome

Ampligen has a shot at becoming the first drug approved for chronic fatigue syndrome, with an advisory panel tentatively slated for Dec. 20. FDA recently unveiled plans to encourage drug development for this condition.

Related Content

Topics

UsernamePublicRestriction

Register

PS053078

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel